TricValve: 12-Month Evolution

Tricuspid regurgitation has become increasingly common, and current pharmacological treatment options are limited. In turn, surgery, which is a complex alternative, carries considerable rates of complications and mortality. In response to this issue, various percutaneous systems are being developed, such as edge-to-edge treatment, percutaneous annuloplasty, and caval valve implantation (CAVI), among others. In the analysis<a href="https://solaci.org/en/2024/01/18/tricvalve-12-month-evolution/" title="Read more" >...</a>

¿Son las válvulas autoexpandibles una opción válida en las bicúspides?

Evolution of Bicuspid Valves at 12 Months

Severe aortic stenosis due to a bicuspid aortic valve (BAV) is uncommon, especially in individuals under 65 years of age. While there are usually no significant differences according to the type of valve when it comes to surgery, with transcatheter aortic valve replacement (TAVR) some may arise.  TAVR has seen significant advancements in the treatment<a href="https://solaci.org/en/2024/01/12/evolution-of-bicuspid-valves-at-12-months/" title="Read more" >...</a>

Sistema EVOQUE: reemplazo tricuspídeo transcatéter, resultados al año

TAVR: High Implantation of Self-Expanding Valves Directly Impacts ECG

TAVR has been shown beneficial, especially in high risk or inoperable patients. However, there are limitations to its use, especially with self-expanding valves, which are the need for pacemaker implantation and ECG changes after procedure.  To address this matter, researchers assessed the right and left cusp overlap effect on 254 patients undergoing TAVR with self-expanding<a href="https://solaci.org/en/2024/01/11/tavr-high-implantation-of-self-expanding-valves-directly-impacts-ecg/" title="Read more" >...</a>

Miami Valves 2024: 35% Discount for SOLACI Members!

From February 1 to 3, 2024, Miami Valves 2024 will be held in Miami, Florida, US, at the Miami Marriot Byscayne Bay Hotel. This event has been founded by faculty members of Miami University centers of excellence and complemented by key opinion leaders from around the world; here you will be able to attend powerful lectures and<a href="https://solaci.org/en/2024/01/08/miami-valves-2024-35-discount-for-solaci-members/" title="Read more" >...</a>

Luz roja para el TAVI en pacientes de bajo riesgo

MYVAL, a TAVR Balloon-Expandable Valve with Promising Results

TAVR has been shown beneficial over time, and with the development of new generation of prosthetic valves and implantation techniques, outcomes have been improved, reducing the incidence of leaks y and the need for definite pacemaker.  This study looked at the evolution of 100 patients with symptomatic aortic stenosis treated with Myval THV from Meril<a href="https://solaci.org/en/2023/12/19/myval-a-tavr-balloon-expandable-valve-with-promising-results/" title="Read more" >...</a>

EVOQUE: Transcatheter Tricuspid Valve Replacement, One-Year Outcomes

Treating tricuspid regurgitation (TR) has gained increasing importance in interventionism. There is abundant literature on the negative natural evolution of this condition and its unfavorable prognosis, as well as the clinical challenges associated to optimal medical treatment.  Among its percutaneous treatment options, both edge-to-edge repair devices (TEER), as showed in TriValve and TRILUMINATE trials, and<a href="https://solaci.org/en/2023/12/15/evoque-transcatheter-tricuspid-valve-replacement-one-year-outcomes/" title="Read more" >...</a>

Intervención tricuspídea heterotópica: Resultados de TricValve a un año

Heterotopic Tricuspid Intervention: TricValve One-Year Outcomes

Severe tricuspid regurgitation (TR) presents a reserved prognosis when not treated in time, seeing as systemic venous congestion might significantly limit quality of life in these patients. For many years it was thought diuretic therapy was the only option to treat these patients, since the surgical alternative offered suboptimal results and many patients were deemed<a href="https://solaci.org/en/2023/12/11/heterotopic-tricuspid-intervention-tricvalve-one-year-outcomes/" title="Read more" >...</a>

Anillos aórticos pequeños, ¿Qué válvula deberíamos elegir?

TAVI-in-TAVI with Balloon-Expandable Valves

TAVI (Transcatheter Aortic Valve Implantation) has proven to be beneficial and is currently performed in increasingly younger and lower-risk patients. However, as with surgical bioprostheses, structural deterioration, whether due to stenosis or regurgitation, is one of the challenges we must address.  While currently uncommon, this is an issue we will probably see more and more<a href="https://solaci.org/en/2023/09/12/tavi-in-tavi-with-balloon-expandable-valves/" title="Read more" >...</a>

Predictors and Evolution of Need for PPM after TAVR with Self-Expanding Valves

In the context of TAVR, one of the current challenges is the need for permanent pacemaker implantation (PPM), especially when using self-expanding valves (SEV). The information available in this regard remains controversial; while some studies suggest new PPM implantation will have no significant effect on clinical evolution, others have associated them with worse prognosis.  As<a href="https://solaci.org/en/2023/09/06/predictors-and-evolution-of-need-for-ppm-after-tavr-with-self-expanding-valves/" title="Read more" >...</a>

Predictors and Evolution of Permanent Pacemaker After TAVR with Self-Expanding Valves

Transcatheter aortic valve replacement (TAVR) has shown remarkable benefits and continues to advance towards lower-risk patients and younger ages. However, one of its limitations lies in the demand for a permanent pacemaker (PPM), which during TAVR early stages with self-expanding valves reached 30%. Uncertainty persists regarding the evolution of patients undergoing PPM implantation after TAVR,<a href="https://solaci.org/en/2023/08/17/predictors-and-evolution-of-permanent-pacemaker-after-tavr-with-self-expanding-valves/" title="Read more" >...</a>